WEBULL
WebtradeDownload

Niagen Bioscience Q2 FY26 net income drops 73.32% to $963,000; net sales fall 4.28% to $29.79 million

PUBT · 1d ago
Niagen Bioscience Q2 FY26 net income drops 73.32% to $963,000; net sales fall 4.28% to $29.79 million
  • Niagen Bioscience posted Q2 net income of USD 963,000, down 73.32% year over year; net sales fell 4% to USD 29.79 million.
  • Consumer Products net sales rose 6% to USD 24.16 million, while Ingredients net sales dropped 29% to USD 5.39 million.
  • Sales and marketing expense climbed to USD 10.13 million from USD 8.21 million, lifting the spend rate to 34% of net sales from 26.4%.
  • Launched the Niagen Plus telehealth platform in May, expanding clinician-directed access to at-home injection kits for eligible U.S. patients.
  • Introduced rare-disease candidate NB4168 for Ataxia-Telangiectasia in July; FDA granted Rare Pediatric Disease designation, EMA granted Orphan Medicinal Product Designation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001386570-26-000043), on August 04, 2026, and is solely responsible for the information contained therein.